Phase II Antifgfr 1 in Nash
Research payments
$6,491,647
Through program year 2024, $6,491,647 in research payments was reported against Phase II Antifgfr 1 in Nash, across 715 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $217,881 | 11 |
| 2023 | Research | $939,706 | 95 |
| 2022 | Research | $2,254,657 | 214 |
| 2021 | Research | $2,312,524 | 249 |
| 2020 | Research | $765,195 | 144 |
| 2019 | Research | $1,684 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stephen Harrison Live Oak, TX Named on 67 payments
- Rashmee Patil Edinburg, TX Named on 39 payments
- Douglas Denham San Antonio, TX Named on 37 payments
- Ben Bostick Cullman, AL Named on 27 payments
- Apurva Modi Fort Worth, TX Named on 21 payments
- Luis Rivera Santa Ana, CA Named on 21 payments
- Grisell Ortiz Lasanta San Juan, PR Named on 21 payments
- Seth Baum Boca Raton, FL Named on 20 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.